Oncologia

Revisão | Abordagem global para melhorar o cuidado no câncer peniano.

6 Mai, 2022 | 17:20h

A global approach to improving penile cancer care – Nature Reviews Urology (se o acesso a este link for pago, tente este)

---

Atualização sobre ablação pulmonar térmica guiada por imagem: diretrizes de sociedade, alternativas terapêuticas e achados de imagem pós-ablação.

6 Mai, 2022 | 16:28h

Update on Image-Guided Thermal Lung Ablation: Society Guidelines, Therapeutic Alternatives, and Postablation Imaging Findings – American Journal of Roentgenology

---

Diretriz clínica SEOM—GECOD para câncer primário desconhecido.

6 Mai, 2022 | 16:27h

SEOM—GECOD clinical guideline for unknown primary cancer (2021) – Clinical and Translational Oncology

---

Recomendações para rastreamento de câncer de mama em mulheres com mamas extremamente densas.

6 Mai, 2022 | 16:26h

Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI) – European Radiology

---

Estudo randomizado | Melhora de sobrevida com enzalutamida em pacientes com câncer de próstata metastático sensível a hormônio.

4 Mai, 2022 | 13:39h

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer – Journal of Clinical Oncology

Estudo original: ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer – Journal of Clinical Oncology

 

Comentário no Twitter

🆕 #JCO #ClinicalTrialUpdate: ARCHES trial – 📈 Enzalutamide + ADT improved OS in men with metastatic horomone-sensitive #ProstateCancer 👉 https://t.co/FQ1lViCTZz #PCSM @AarmstrongDuke pic.twitter.com/fLs6PdFYlr

— Journal of Clinical Oncology (@JCO_ASCO) April 27, 2022

 

---

Estudo randomizado | Tislelizumabe vs. quimioterapia como tratamento de segunda linha para carcinoma esofágico de células escamosas avançado ou metastático.

4 Mai, 2022 | 13:37h

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study – Journal of Clinical Oncology

 

Comentário no Twitter

In the phase III RATIONALE-302 trial of tislelizumab vs chemotherapy as 2nd-line therapy for advanced-stage ESCC, mOS was 8.6 vs 6.3 months (HR 0.70; P=0.0001), rising to 10.3 vs 6.8 months for those with a PD-L1 tumour area positivity score >10%: https://t.co/CNxads2Kn2 #esocsm

— NatureRevClinOncol (@NatRevClinOncol) April 27, 2022

 

---

M-A | Definição de câncer esofagogástrico oligometastático e impacto do tratamento local direcionado à oligometástase.

4 Mai, 2022 | 13:32h

Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis – European Journal of Cancer

---

Estudo randomizado | Imiquimod tópico vs. cirurgia para neoplasia intraepitelial vulvar.

4 Mai, 2022 | 13:31h

Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial – The Lancet (link para o resumo – $ para o texto completo)

---

Estudo randomizado | Monitoramento remoto digital com cuidado padrão vs. cuidado padrão em pacientes tratados com agentes anticâncer orais.

3 Mai, 2022 | 16:43h

Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial – Nature Medicine (se o acesso a este link for pago, tente este)

 

Comentário no Twitter

A phase 3 clinical trial evaluating the impact of a digital nurse navigator-led system in patients receiving oral #cancer treatment shows that remote monitoring with a smartphone results in improved patient experience & optimizes resources @GustaveRoussy https://t.co/N8fEXb00r7

— Nature Medicine (@NatureMedicine) April 26, 2022

 

---

Estudo randomizado | Eficiência da avaliação por prontuário eletrônico de desfechos relatados pelo paciente após imunoterapia para câncer.

3 Mai, 2022 | 16:42h

Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy: A Randomized Clinical Trial – JAMA Network Open

Comentário convidado: An Assistive Electronic Patient-Reported Outcome Monitoring Intervention for Management of Immune-Related Toxic Effects—Moving Toward Efficiency and Scale – JAMA Network Open

 

Comentário no Twitter

This RCT aimed to compare the efficiency between ePRO and traditional follow up models in cancer immunotherapy among 278 patients from 28 hospitals, finding that an ePRO model can improve safety & QOL, and is less time consuming. https://t.co/KtpcNz0keb pic.twitter.com/EsmNyTkdfB

— JAMA Network Open (@JAMANetworkOpen) March 31, 2022

 

---